ERBB2 and breast carcinoma: In patients with breast cancer, the outcome of prediction and treatment response depends on immunohistochemical (IHC) markers such as ER, PR, and HER-2, as well as standard clinicopathologic features such as tumor size, grade, and lymph node involvement, which often exhibit potentially different outcomes due to other clinical manifestations and molecular characteristics.